TOVX Latest Press Releases

-- September 30, 2026 --

Theriva Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine Globe Newswire 8:00 AM

-- August 11, 2026 --

Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results Globe Newswire 8:00 AM

-- August 6, 2026 --

Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma Globe Newswire 8:00 AM

-- July 7, 2026 --

Theriva Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma Globe Newswire 8:00 AM

-- June 11, 2026 --

Theriva Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes